

Table 1: Cohort Description

	Individuals without T2D Diagnosis	Individuals with T2D Diagnosis
	(n = 366,779)	(n= 43,610)
Baseline Characteristics		
Sex [% males] (counts)	43.48 (159,476)	58.71 (25,603)
Age at recruitment [years] *	56.16 ± 8.12	58.53 ± 7.54
Deceased [%] (counts)	3.03 (11,116)	5.85 (2,551)
Age at death [years] *	70.23 ± 7.29	71.75 ± 6.57
Morbidities [%] (counts)		
Cancer	7.34 (26,793)	7.78 (3,360)
Fractured/broken bones	9.48 (34,520)	8.93 (3,846)
Other serious medical condition/disability	18.94 (68,129)	27.90 (11,725)
Cardiovascular disease	25.72 (93,960)	58.30 (25,200)
Blood clots, DVT, bronchitis, emphysema	3.62 (13,237)	6.29 (2,714)
Traits		
Townsend deprivation index *	-1.42 ± 3.00	-0.47 ± 3.40
Sleep duration [hours] *	7.15 ± 1.07	7.14 ± 1.31
Smoking [PackYears] *	7.21 ± 14.17	13.03 ± 20.72
Body fat [%] *	31.07 ± 8.48	34.33 ± 8.46
Physical exercise [Summed MET minutes/ week] *	2,707.73 ± 2,725.36	2,367.37 ± 2,675.11
Alcohol intake [weekly units] *	7.50 ± 8.92	6.07 ± 9.20
Body mass index [kg/m2] *	26.91 ± 4.43	31.44 ± 5.51
Anti-diabetic Drug Use [%] (counts)		
Metformin	0.11 (400)	57.45 (25,056)
Sulfonylureas	0.01 (40)	16.47 (7,181)
Long/Interm.-Acting Insulins	0.22 (811)	14.40 (6,281)
DPP4I	0.01 (35)	13.66 (5,959)
SGLT2I	0.01 (25)	8.49 (3,703)
Short-Acting Insulins	0.17 (637)	6.45 (2,813)
GLP1RA	0.00 (14)	4.20 (1,833)
Thiazolidinediones	0.00 (4)	1.75 (765)
Meglitinides	0.00 (0)	0.12 (52)
Acarbose	0.00 (7)	0.03 (14)

*mean ± standard deviation